Safety and Feasibility of Riociguat Therapy for the Treatment of Chronic Pulmonary Arterial Hypertension in Infancy - 19/04/23
Doi : 10.1016/j.jpeds.2022.11.026
Regan E. Giesinger, MD 1, ⁎ 
, Amy H. Stanford, MD 1, Brady Thomas, MD 1, Steven H. Abman, MD 2, Patrick J. McNamara, MB, BCH, BAO 1
, Amy H. Stanford, MD 1, Brady Thomas, MD 1, Steven H. Abman, MD 2, Patrick J. McNamara, MB, BCH, BAO 1 1 Department of Pediatrics, University of Iowa, Iowa City, IA
2 Department of Pediatrics, University of Colorado, Denver, CO
∗Reprint requests: Regan E. Giesinger, MD, University of Iowa, 200 Hawkins Dr, Iowa City, IA 52242.University of Iowa200 Hawkins DrIowa CityIA52242
Abstract |
The effects of riociguat, an oral-soluble guanylate-cyclase stimulator, were studied in 10 infants with chronic pulmonary arterial hypertension. Respiratory status (n = 8/10), right heart dilation (n = 7/10), function (n = 9/10), and chronic pulmonary arterial hypertension (n = 8/10) improved. Median decrement in systolic (12 [4, 14]), diastolic (14 [7, 20]), and mean arterial (14 [10, 17]) pressures were noted; no critical hypotension or hypoxemia occurred.
Le texte complet de cet article est disponible en PDF.Abbreviations : BPD, CPAH, FiO2, iNO, NO, PDE-5, PVR, Q8h, RV, sCG, TnECHO
Plan
| The authors declare no conflicts of interest. |
© 2022
Elsevier Inc. Tous droits réservés.
Vol 255
P. 224 - avril 2023 Retour au numéro
Article précédent
- Evidence Suggests a Decrease in the Incidence of Kernicterus in California
- Lucas Walz, Jordan C. Brooks, Thomas Newman
- Hemodynamic Characterization of Neonates With Congenital Diaphragmatic Hernia–Associated Pulmonary Hypertension by Cardiac Catheterization
- Paula Dias Maia, Jason Gien, John P. Kinsella, Jenny Zablah, Gareth Morgan, D. Dunbar Ivy, Steven H. Abman, Benjamin S. Frank
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?